Singapore: Japanese firm, Mitsubishi Electric Corporation, is gearing up to solidify its presence in the bioscience sector. The company has expanded its particle therapy business in Japan and global markets by forming a medical system global marketing group at its Tokyo headquarters and a particle therapy medical group at Mitsubishi Electric Power Products (MEPPI), a US-based subsidiary.

Mistubishi has reported that a team in the new medical system global marketing group in Tokyo is now studying marketing opportunities in the global medical markets, including analysis of specific markets to adapt solutions to local needs. As part of this effort, a fully operational proton accelerator has been installed at Energy Systems Center in Kobe to test innovations in a controlled laboratory. This eliminates the need to rely on the use of customers clinical systems to validate new developments, and will give clinics the added assurance of knowing that these solutions were tested fully and rigorously prior to clinical implementation.

In addition to the focus at the headquarters, the company has dispatched a team of experts to establish the particle therapy medical group in the Warrendale, Pennsylvania headquarters of MEPPI.

Mitsubishi has also set up a global medical device quality management system establishment and maintenance project group, a dedicated regulatory group to address specific requirements in each country.